tetano
Editor, Senior Moderator
J Neurol Sci
. 2020 Jun 3;415:116969.
doi: 10.1016/j.jns.2020.116969. Online ahead of print.
Neurological Manifestations and COVID-19: Experiences From a Tertiary Care Center at the Frontline
Pranusha Pinna[SUP] 1 [/SUP], Parneet Grewal[SUP] 2 [/SUP], Julianne P Hall[SUP] 2 [/SUP], Tachira Tavarez[SUP] 2 [/SUP], Rima M Dafer[SUP] 2 [/SUP], Rajeev Garg[SUP] 2 [/SUP], Nicholas D Osteraas[SUP] 2 [/SUP], Danielle R Pellack[SUP] 2 [/SUP], Anjali Asthana[SUP] 2 [/SUP], Kelsey Fegan[SUP] 2 [/SUP], Vikram Patel[SUP] 2 [/SUP], James J Conners[SUP] 2 [/SUP], Sayona John[SUP] 2 [/SUP], Ivan Da Silva[SUP] 2 [/SUP]
Affiliations
Abstract
Objective: To report neurological manifestations seen in patients hospitalized with Coronavirus disease 2019 (COVID-19) from a large academic medical center in Chicago, Illinois.
Methods: We retrospectively reviewed data records of 50 patients with COVID-19 who were evaluated by the neurology services from March 1, 2020 - April 30, 2020. Patients were categorized into 2 groups based on timing of developing neurological manifestations: the "Neuro first" group had neurological manifestations upon initial assessment, and the "COVID first" group developed neurological symptoms greater than 24 h after hospitalization. The demographics, comorbidities, disease severity and neurological symptoms and diagnoses of both groups were analyzed. Statistical analysis was performed to compare the two groups.
Results: A total of 50 patients (48% African American and 24% Latino) were included in the analysis. Most common neurological manifestations observed were encephalopathy (n = 30), cerebrovascular disease (n = 20), cognitive impairment (n = 13), seizures (n = 13), hypoxic brain injury (n = 7), dysgeusia (n = 5), and extraocular movement abnormalities (n = 5). The "COVID-19 first" group had more evidence of physiologic disturbances on arrival with a more severe/critical disease course (83.3% vs 53.8%, p 0.025).
Conclusion: Neurologic manifestations of COVID-19 are highly variable and can occur prior to the diagnosis of or as a complication of the viral infection. Despite similar baseline comorbidities and demographics, the COVID-19 patients who developed neurologic symptoms later in hospitalization had more severe disease courses. Differently from previous studies, we noted a high percentage of African American and Latino individuals in both groups.
. 2020 Jun 3;415:116969.
doi: 10.1016/j.jns.2020.116969. Online ahead of print.
Neurological Manifestations and COVID-19: Experiences From a Tertiary Care Center at the Frontline
Pranusha Pinna[SUP] 1 [/SUP], Parneet Grewal[SUP] 2 [/SUP], Julianne P Hall[SUP] 2 [/SUP], Tachira Tavarez[SUP] 2 [/SUP], Rima M Dafer[SUP] 2 [/SUP], Rajeev Garg[SUP] 2 [/SUP], Nicholas D Osteraas[SUP] 2 [/SUP], Danielle R Pellack[SUP] 2 [/SUP], Anjali Asthana[SUP] 2 [/SUP], Kelsey Fegan[SUP] 2 [/SUP], Vikram Patel[SUP] 2 [/SUP], James J Conners[SUP] 2 [/SUP], Sayona John[SUP] 2 [/SUP], Ivan Da Silva[SUP] 2 [/SUP]
Affiliations
- PMID: 32570113
- DOI: 10.1016/j.jns.2020.116969
Abstract
Objective: To report neurological manifestations seen in patients hospitalized with Coronavirus disease 2019 (COVID-19) from a large academic medical center in Chicago, Illinois.
Methods: We retrospectively reviewed data records of 50 patients with COVID-19 who were evaluated by the neurology services from March 1, 2020 - April 30, 2020. Patients were categorized into 2 groups based on timing of developing neurological manifestations: the "Neuro first" group had neurological manifestations upon initial assessment, and the "COVID first" group developed neurological symptoms greater than 24 h after hospitalization. The demographics, comorbidities, disease severity and neurological symptoms and diagnoses of both groups were analyzed. Statistical analysis was performed to compare the two groups.
Results: A total of 50 patients (48% African American and 24% Latino) were included in the analysis. Most common neurological manifestations observed were encephalopathy (n = 30), cerebrovascular disease (n = 20), cognitive impairment (n = 13), seizures (n = 13), hypoxic brain injury (n = 7), dysgeusia (n = 5), and extraocular movement abnormalities (n = 5). The "COVID-19 first" group had more evidence of physiologic disturbances on arrival with a more severe/critical disease course (83.3% vs 53.8%, p 0.025).
Conclusion: Neurologic manifestations of COVID-19 are highly variable and can occur prior to the diagnosis of or as a complication of the viral infection. Despite similar baseline comorbidities and demographics, the COVID-19 patients who developed neurologic symptoms later in hospitalization had more severe disease courses. Differently from previous studies, we noted a high percentage of African American and Latino individuals in both groups.